TREM2, a receptor expressed on tumor-associated macrophages (TAMs), plays a critical role in pancreatic ductal adenocarcinoma (PDAC). Researchers explored its function by genetically removing TREM2 in a transgenic mouse model (KPPC;Trem2−/−) to study PDAC progression.
TREM2, a receptor expressed on tumor-associated macrophages (TAMs), plays a critical role in pancreatic ductal adenocarcinoma (PDAC). Researchers explored its function by genetically removing TREM2 in a transgenic mouse model (KPPC;Trem2−/−) to study PDAC progression. Surprisingly, the absence of TREM2 accelerated tumor growth and reduced survival, showing that TREM2 has a protective, anti-inflammatory role rather than promoting cancer.
Single-cell RNA sequencing revealed that TREM2 depletion caused an increase in proinflammatory macrophages, leading to chronic inflammation in the tumor microenvironment. Mechanistic studies identified TREM2 as a key regulator that suppresses the NLRP3/NF-κB/IL-1β inflammasome pathway, preventing excessive inflammatory signaling. Without TREM2, this pathway becomes overactive, driving harmful inflammation.
Additionally, microbial lipopolysaccharide (LPS) from the gut microbiome worsened inflammation in TREM2-deficient mice, further increasing IL-1β levels and accelerating PDAC progression. This highlights the connection between the gut microbiome and cancer-related inflammation.
Importantly, researchers found that blocking IL-1β or depleting the microbiome reversed the rapid tumor progression caused by TREM2 loss, emphasizing the pathogenic role of IL-1β in PDAC. These findings suggest that TREM2 functions as an anti-inflammatory checkpoint, maintaining immune balance by controlling macrophage-driven inflammation.
Clinically, targeting the IL-1β pathway or modulating TREM2 activity could offer new therapeutic strategies to reduce inflammation and improve outcomes in pancreatic cancer patients. This research redefines the role of TREM2 in PDAC and opens the door for novel approaches to combat tumor-promoting inflammation.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.